Amsterdam Molecular Therapeutics Successfully Raised EUR 14.3 m Through an Equity Issue

AMSTERDAM, October 6, 2010 - Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext:
AMT) announces today that it has successfully raised EUR 14.3 m in gross
proceeds through a private placement of new shares with institutional
investors, other qualifying investors who subscribed for at least EUR 50,000
per investor in various jurisdictions and the members of the Board of
Management (the "Private Placement"). Pursuant to the Private Placement AMT
will issue 8,435,294 new ordinary shares with a nominal value of EUR 0.04
each for an offer price of EUR 1.70 per share.

The net proceeds of the Private Placement will increase AMT's
financial flexibility and will be used to fund Glybera(R) through its
regulatory and commercial development and to continue the development of the
hemophilia and other pipeline programs.

The payment and delivery of the new shares is expected to take
place on October 11, 2010, at which date the new shares are also expected to
be admitted to listing on NYSE Euronext in Amsterdam.

Immediately after the closing of the Private Placement, AMT's
issued and outstanding share capital will amount to 23,504,022 ordinary
shares.

Pricing Statement

The prospectus that was prepared in relation to the admission to listing
and trading of the shares was made generally available on 5 October 2010.
Today, AMT deposited a pricing statement with the Authority of the Financial
Markets (Stichting Autoriteit Financiële Markten) mentioning amongst others
the number of new shares to be issued and the issue price of the new shares.
The prospectus and the pricing statement are available via AMT's website.

Kempen & Co and Petercam Nederland N.V. have acted as joint global
coordinators and bookrunners for the Private Placement.

About Amsterdam Molecular Therapeutics

AMT is a leader in the development of human gene based
therapies. Using adeno-associated viral (AAV) derived vectors as the delivery
vehicle of choice for therapeutic genes, the company has been able to design
and validate what is probably the first stable and scalable AAV production
platform. This proprietary platform can be applied to a large number of rare
(orphan) diseases that are caused by one faulty gene. Currently, AMT has a
product pipeline with several AAV-based gene therapy products in LPLD,
Hemophilia B, Duchenne Muscular Dystrophy, Acute Intermittent Porphyria, and
Parkinson's Disease at different stages of research or development. AMT was
founded in 1998 and is based in Amsterdam.

Not for release, publication or distribution in whole or in
part, directly or indirectly, in or into the United States, Australia,
Canada, Japan or South Africa or to US persons. This announcement is not a
prospectus and is not an offer for sale of securities in the United States,
Canada, South Africa, Australia, Japan or any other jurisdiction.

The securities mentioned herein have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the "Securities
Act"), and may not be offered or sold in the United States absent
registration under the Securities Act or an available exemption from, or in a
transaction not subject to, the registration requirements of the Securities
Act.

In connection with the admission of the shares in the capital
of Amsterdam Molecular Therapeutics (AMT) Holding N.V. to listing and trading
on NYSE Euronext in Amsterdam a prospectus has been made generally available
(the "Prospectus"). The Prospectus is available at no cost through the
website of AMT, and is also available via the website of NYSE Euronext (Dutch
residents only) and by sending a request in writing to AMT (P.O. Box 22506,
1100 DA Amsterdam, The Netherlands).

————————————————————————-

Certain statements in this press release are "forward-looking
statements" including those that refer to management's plans and expectations
for future operations, prospects and financial condition. Words such as
"strategy," "expects," "plans," "anticipates," "believes," "will,"
"continues," "estimates," "intends," "projects," "goals," "targets" and other
words of similar meaning are intended to identify such forward-looking
statements. Such statements are based on the current expectations of the
management of AMT only. Undue reliance should not be placed on these
statements because, by their nature, they are subject to known and unknown
risks and can be affected by factors that are beyond the control of AMT.
Actual results could differ materially from current expectations due to a
number of factors and uncertainties affecting AMT's business.

AMT expressly disclaims any intent or obligation to update any
forward-looking statements herein except as required by law. For a more
detailed description of the risk factors and uncertainties affecting AMT,
reference is made to the Prospectus and AMT's public announcements made from
time to time.

PRN NLD

For further enquiries: Ellen Roest, AMT Communications, Tel: +31-6-2900-6179, e.roest at amtbiopharma.com; Mike Sinclair, Halsin Partners, Tel: +44-20-7318 2955, msinclair at halsin.com; Jörn Aldag, CEO, Tel +31-20-566-7394, j.aldag at amtbiopharma.com